SteadyMed Completes Program of Human Factors Studies Validating Usability of Trevyent
July 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., July 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
June 29, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
SteadyMed Adds Significant Commercial Expertise to Its Board of Directors With the Appointment of Elizabeth A. Cermak
June 18, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
SteadyMed to Present at the JMP Securities Life Sciences Conference
June 16, 2015 11:40 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value...
CORRECTING and REPLACING - SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results
May 14, 2015 08:53 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by SteadyMed Ltd. (Nasdaq:STDY), please note that in the first paragraph under the First...
SteadyMed Reports Recent Developments, Financial Highlights and First Quarter 2015 Financial Results
May 14, 2015 07:39 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases...
SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension
May 07, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug...
SteadyMed Granted Additional U.S. Patent With Patent Term Extension
April 22, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced the issuance of a new patent from the United States Patent and...
SteadyMed Appoints David W. Nassif as Its Full Time Executive Vice President and Chief Financial Officer
April 08, 2015 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company, today announced the appointment of David W. Nassif as its full time Executive...
SteadyMed Announces Closing of Initial Public Offering
March 25, 2015 14:26 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd., a specialty pharmaceutical company, today announced the closing of its initial public offering of 4,700,000 ordinary shares at a...